The associations between asthma age-of-onset phenotypes and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive test by treatment and lung function
| Early onset | Late onset | |||
|---|---|---|---|---|
| Percentage of positive tests (n/N) | OR (95% CI) for a positive test | Percentage of positive tests (n/N) | OR (95% CI) for a positive test | |
| Asthma treatment | ||||
| No | 15.8 (491/3114) | Ref | 18 (672/3727) | Ref |
| Treated with non-steroid | 17.3 (112/645) | 1.05 (0.81–1.36), p=0.67 | 16.5 (261/1576) | 0.90 (0.75–1.08), p=0.26 |
| Treated with steroids | 16.6 (284/1710) | 1.18 (0.98–1.42), p=0.07 | 17.1 (719/4216) | 1.04 (0.91–1.19), p=0.55 |
| Quartiles of baseline FEV1 | ||||
| Q1 of FEV1 (lowest quartile) | 12.4 (70/562) | Ref | 18.3 (190/1035) | Ref |
| Q2 of FEV1 | 16.7 (120/715) | 1.25 (0.88–1.79), p=0.20 | 15.2 (203/1332) | 0.81 (0.64–1.03), p=0.09 |
| Q3 of FEV1 | 14.8 (145/976) | 1.22 (0.87–1.72), p=0.23 | 16.9 (280/1653) | 0.92 (0.73–1.15), p=0.48 |
| Q4 of FEV1 | 16.7 (310/1851) | 1.44 (1.05–1.72), p=0.02 | 17.4 (516/2962) | 0.90 (0.73–1.15), p=0.36 |
FEV1: forced expiratory volume in 1 s.